Vertex Pharmaceuticals faced a challenging start to 2026, but has rebounded recently, with a 10% stock gain over the past month and a year-to-date increase of 9%. Key developments fueling this optimism include a label expansion for its gene-editing medicine, Casgevy, allowing treatment for younger patients with sickle cell disease and beta-thalassemia, thereby adding 5,500 potential patients. Additionally, Vertex is awaiting approval for povetacicept for IgA nephropathy, which could significantly boost sales. Other late-stage therapies and the recent $10 billion acquisition of Crinetics Pharmaceuticals also promise strong financial growth. Overall, Vertex’s core business in cystic fibrosis remains robust, and the company’s diversified product pipeline suggests promising prospects for future growth.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/investing/2026/07/10/is-this-biotech-stock-a-buy-near-its-52-week-high/
